Rina-S vs standard therapy for advanced endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that has come back or gotten worse after treatment, and it is not a rare subtype like neuroendocrine or sarcoma.
- You have had between 1 and 3 prior treatments, including platinum chemo and an immunotherapy drug (like Keytruda or Tecentriq).
- You have not had an antibody-drug conjugate that targets topoisomerase 1 (like Trodelvy or Enhertu).
- You do not have active brain metastases unless they've been stable for at least 4 weeks and you're off steroids/anticonvulsants for brain symptoms.
- You have not had a bowel blockage recently or currently have one that requires IV nutrition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
This trial tests a combination of two drugs—nab-sirolimus and letrozole—for people with advanced or returning endometrioid endometrial cancer. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a new drug, cadonilimab (AK104), combined with chemotherapy for women with advanced or recurrent endometrial cancer. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This trial tests whether adding a targeted therapy called fruquintinib (a type of anti-angiogenesis drug) to standard chemotherapy (paclitaxel and carboplatin) is more effective than chemotherapy alone for advanced or recurrent endometrial cancer that is not dMMR. If you haven't had prior systemic therapy for advanced disease and your tumor is pMMR, this could be an option.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.